IDIBELL project, funded by EMBO


Dr. Antonio Gentilella has get an EMBO Long-Term Fellowship The project, leaded by Dr. Antonio Gentilella and funded by an EMBO Long-Term Fellowship, is focussed on understanding the mechanisms by which the tumor suppressor p53, also known as the guardian of genome, is activated in response to ribosomal impairment, a cause of two rare anemias, DBA and 5-syndrome, both of which have the propensity to develop into cancer in later life.

Dr. Gentilella has recently joined George Thomas’s group at the IDIBELL from the University of Pennsylvania, Philadelphia, PA.

Scroll to Top